Literature DB >> 8801201

Increased degradation of type I collagen in patients with inflammatory bowel disease.

J Silvennoinen1, L Risteli, T Karttunen, J Risteli.   

Abstract

To assess the mechanisms of osteopenia in inflammatory bowel disease (IBD), the serum markers of bone formation (osteocalcin and carboxyterminal propeptide of type I procollagen (PICP)) and bone degradation (carboxyterminal telopeptide of type I collagen (ICTP)), the bone mineral density (BMD) of the lumbar spine and the proximal femur and calcium intake of 150 unselected IBD patients and 73 healthy controls were investigated. The patients had higher ICTP values (3.69 (SD 1.40) microgram/l) than the healthy controls (3.25 (1.00) microgram/l, p = 0.035), but no differences in serum PICP and osteocalcin between these groups were detected. In the patients, the ICTP, PICP, and osteocalcin values did not have any significant correlation with BMD, but the patients with ICTP values above 3.6 microgram/l had significantly lower Z scores than those with lower ICTP. In the controls, however, a positive correlation between serum ICTP and BMD was found. The ulcerative colitis patients with total colitis had higher values of ICTP (3.96 (1.58) microgram/l) than those with a left sided disease (3.04 (0.86) micrograms/l, p = 0.009). The patients with a history of clinically active disease (n = 20) had higher ICTP (4.58 (1.55) microgram/l) and osteocalcin (12.56 (5.64) microgram/l) values than the patients (n = 130) with quiescent disease (ICTP 3.56 (1.33), p = 0.002, and osteocalcin 9.76 (3.62), p = 0.017). Increased serum osteocalcin, PICP, and ICTP concentrations and reduced BMD Z scores were found in a subgroup of Crohn's disease patients with a history of an active disease (n = 11). Raised serum ICTP and normal values of osteocalcin and PICP in IBD patients show increased breakdown of type I collagen without a compensatory increase in its synthesis suggesting an increased rate of bone degradation as a probable mechanism for osteopenia in IBD. Raised ICTP values are related to reduced bone mineral densities.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8801201      PMCID: PMC1383027          DOI: 10.1136/gut.38.2.223

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  21 in total

1.  A simple index for assessment of disease activity in patients with ulcerative colitis.

Authors:  I Rutegård; L Ahsgren; R Stenling; T Nilsson
Journal:  Hepatogastroenterology       Date:  1990-12

2.  Dual-energy X-ray absorptiometry in normal women: a cross-sectional study of 717 Finnish volunteers.

Authors:  H Kröger; J Heikkinen; K Laitinen; A Kotaniemi
Journal:  Osteoporos Int       Date:  1992-05       Impact factor: 4.507

3.  External thoracic duct-venous shunt in conscious pigs for long term studies of connective tissue metabolites in lymph.

Authors:  L T Jensen; H P Olesen; J Risteli; I Lorenzen
Journal:  Lab Anim Sci       Date:  1990-11

4.  Systemic glucocorticoid treatment decreases serum concentrations of carboxyterminal propeptide of type I procollagen and aminoterminal propeptide of type III procollagen.

Authors:  A Oikarinen; P Autio; J Vuori; K Väänänen; L Risteli; U Kiistala; J Risteli
Journal:  Br J Dermatol       Date:  1992-02       Impact factor: 9.302

5.  Osteoporosis in patients with inflammatory bowel disease.

Authors:  J E Compston; D Judd; E O Crawley; W D Evans; C Evans; H A Church; E M Reid; J Rhodes
Journal:  Gut       Date:  1987-04       Impact factor: 23.059

6.  Synthesis of type I collagen in healing wounds in humans.

Authors:  K Haukipuro; J Melkko; L Risteli; M Kairaluoma; J Risteli
Journal:  Ann Surg       Date:  1991-01       Impact factor: 12.969

7.  A new method to measure type I and III collagen synthesis in human skin in vivo: demonstration of decreased collagen synthesis after topical glucocorticoid treatment.

Authors:  A Oikarinen; P Autio; U Kiistala; L Risteli; J Risteli
Journal:  J Invest Dermatol       Date:  1992-02       Impact factor: 8.551

8.  A controlled study of bone mineral density in patients with inflammatory bowel disease.

Authors:  J A Silvennoinen; T J Karttunen; S E Niemelä; J J Manelius; J K Lehtola
Journal:  Gut       Date:  1995-07       Impact factor: 23.059

9.  Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen.

Authors:  J Melkko; S Niemi; L Risteli; J Risteli
Journal:  Clin Chem       Date:  1990-07       Impact factor: 8.327

10.  Histological diagnosis of chronic inflammatory bowel disease in childhood.

Authors:  S K Chong; A J Blackshaw; S Boyle; C B Williams; J A Walker-Smith
Journal:  Gut       Date:  1985-01       Impact factor: 23.059

View more
  12 in total

Review 1.  Bone abnormalities in gastrointestinal and hepatic disease.

Authors:  F A Sylvester
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

Review 2.  Advances in the understanding of mineral and bone metabolism in inflammatory bowel diseases.

Authors:  Fayez K Ghishan; Pawel R Kiela
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-11-18       Impact factor: 4.052

3.  Mutifactorial analysis of risk factors for reduced bone mineral density in patients with Crohn's disease.

Authors:  Sarah A Bartram; Robert T Peaston; David J Rawlings; David Walshaw; Roger M Francis; Nick P Thompson
Journal:  World J Gastroenterol       Date:  2006-09-21       Impact factor: 5.742

4.  Effects of surgery on peripheral N-terminal propeptide of type III procollagen in patients with Crohn's disease.

Authors:  Matilde De Simone; Michele M Ciulla; Ugo Cioffi; Luca Poggi; Barbara Oreggia; Roberta Paliotti; Fiorenzo Botti; Alberto Carrara; Fiorenza Agosti; Alessandro Sartorio; Ettore Contessini-Avesani
Journal:  J Gastrointest Surg       Date:  2007-08-09       Impact factor: 3.452

Review 5.  Extraintestinal manifestations and complications in inflammatory bowel diseases.

Authors:  Katja S Rothfuss; Eduard F Stange; Klaus R Herrlinger
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

Review 6.  Clinical relevance of changes in bone metabolism in inflammatory bowel disease.

Authors:  Pal Miheller; Katalin Lorinczy; Peter-Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2010-11-28       Impact factor: 5.742

7.  Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea.

Authors:  Dale A Fritsch; Matthew I Jackson; Susan M Wernimont; Geoffrey K Feld; Jennifer M MacLeay; John J Brejda; Chun-Yen Cochrane; Kathy L Gross
Journal:  BMC Vet Res       Date:  2022-06-24       Impact factor: 2.792

8.  Allelic variation at the interleukin 1beta gene is associated with decreased bone mass in patients with inflammatory bowel diseases.

Authors:  A Nemetz; M Tóth; M A García-González; T Zágoni; J Fehér; A S Peña; Z Tulassay
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

Review 9.  The efficacy and safety of bisphosphonates for osteoporosis or osteopenia in Crohn's disease: a meta-analysis.

Authors:  Zhen Guo; Rong Wu; Jianfeng Gong; Weiming Zhu; Yi Li; Ning Li; Jieshou Li
Journal:  Dig Dis Sci       Date:  2012-11-20       Impact factor: 3.199

10.  Elevated serum procollagen type III peptide in splanchnic and peripheral circulation of patients with inflammatory bowel disease submitted to surgery.

Authors:  Matilde De Simone; Ugo Cioffi; Ettore Contessini-Avesani; Barbara Oreggia; Roberta Paliotti; Alberto Pierini; Gianni Bolla; Elide Oggiano; Stefano Ferrero; Fabio Magrini; Michele M Ciulla
Journal:  BMC Gastroenterol       Date:  2004-11-04       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.